SS-Inclisiran sodium（Cat No.:I043631）is a modified version of Inclisiran, an RNA interference (RNAi) therapy designed to lower LDL cholesterol levels by targeting and silencing the PCSK9 gene. This modification, involving a sulfonate group (SS), enhances the stability and pharmacokinetic profile of Inclisiran, improving its effectiveness and duration of action. By inhibiting PCSK9, SS-Inclisiran sodium increases the liver’s ability to clear LDL cholesterol from the bloodstream, offering a potential treatment for patients with hypercholesterolemia and those at risk for cardiovascular diseases. This drug represents a promising approach in lipid-lowering therapies.